SUN PHARMACEUTICAL INDUSTRIES LTD. - 524715 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
Intimation of Schedule of Analyst/Institutional Investor Meeting24-08-2023
24-08-2023
Navigating Deuruxolitinib's road: HSBC and Nomura weigh in on Sun Pharma's outlook
HSBC and Nomura maintain buy ratings, with HSBC increasing target price to Rs 1275 ( 13.5% from earlier) and Nomura to Rs 1313 (from Rs 1138).24-08-2023
SUN PHARMACEUTICAL INDUSTRIES LTD. - 524715 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
Intimation of Loss of share certificate19-08-2023
SUN PHARMACEUTICAL INDUSTRIES LTD. - 524715 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
Intimation of Schedule of Analyst/Institutional Investor Meeting16-08-2023
SUN PHARMACEUTICAL INDUSTRIES LTD. - 524715 - Disclosure Under Regulation 30A Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015
Disclosure under regulation 30A14-08-2023
SUN PHARMACEUTICAL INDUSTRIES LTD. - 524715 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
Intimation for Issuance of Duplicate share certificate under Regulation 39(3) of SEBI LODR 201511-08-2023
SUN PHARMACEUTICAL INDUSTRIES LTD. - 524715 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
Intimation under Regulation 39(3) of SEBI LODR 2015.11-08-2023
SUN PHARMACEUTICAL INDUSTRIES LTD. - 524715 - Announcement under Regulation 30 (LODR)-Earnings Call Transcript
Q1 FY24 Earnings Call Transcript09-08-2023
Buy Sun Pharmaceutical Industries; target of Rs 1265: Prabhudas Lilladher
Prabhudas Lilladher is bullish on Sun Pharmaceutical Industries has recommended buy rating on the stock with a target price of Rs 1265 in its research report dated August 03, 2023.07-08-2023